PT  - JOURNAL ARTICLE
AU  - Liu, Lunan
AU  - Ma, Chao
AU  - Zhang, Zhuoyu
AU  - Chen, Weqiang
TI  - A computational model of CAR T-cell immunotherapy predicts leukemia patient responses at remission, resistance, and relapse
AID  - 10.1101/2021.09.21.21263913
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.21.21263913
4099  - http://medrxiv.org/content/early/2021/09/23/2021.09.21.21263913.short
4100  - http://medrxiv.org/content/early/2021/09/23/2021.09.21.21263913.full
AB  - Adaptive CD19-targeted CAR (Chimeric Antigen Receptor) T-cell transfer has become a promising treatment for leukemia. Though patient responses vary across different clinical trials, there currently lacks reliable early diagnostic methods to predict patient responses to those novel therapies. Recently, computational models achieve to in silico depict patient responses, with prediction application being limited. We herein established a computational model of CAR T-cell therapy to recapitulate key cellular mechanisms and dynamics during treatment based on a set of clinical data from different CAR T-cell trials, and revealed critical determinants related to patient responses at remission, resistance, and relapse. Furthermore, we performed a clinical trial simulation using virtual patient cohorts generated based on real clinical patient dataset. With input of early-stage CAR T-cell dynamics, our model successfully predicted late responses of various virtual patients compared to clinical observance. In conclusion, our patient-based computational immuno-oncology model may inform clinical treatment and management.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Science Foundation (CBET 2103219), the US National Institutes of Health (R35GM133646). C.M. is the recipient of a Cancer Research Institute Irvington Postdoctoral Fellowship (CRI4018).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a computational study therefore does not require IRB approval. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the relevant data are included in the manuscript and its supplementary material file. The code for the computational model is available on Github (https://github.com/Lunan12/CAR-T-model). https://github.com/Lunan12/CAR-T-model